Australia Legal Cannabis Market By Source (Hemp, Marijuana), By Derivatives (CBD, THC, Others), By Cultivation (Indoor Cultivation, Greenhouse Cultivation, Outdoor Cultivation), By End Use (Industrial Use, Medical Use, Recreational Use), By Region and Competition, Forecast & Opportunities, 2021-2031F

Key Insights	Details
Forecast Period	2027-2031
Market Size (2025)	USD 486.92 Million
CAGR (2026-2031)	13.84%
Fastest Growing Segment	Medical Use
Largest Market	Victoria
Market Size (2031)	USD 1059.81 Million

Market Overview

The Australia Legal Cannabis Market will grow from USD 486.92 Million in 2025 to USD 1059.81 Million by 2031 at a 13.84% CAGR. The Australia Legal Cannabis Market predominantly comprises medicinal cannabis products authorized for therapeutic applications under a comprehensive federal and state regulatory framework. Market expansion is primarily driven by increasing government approvals through established pathways, growing awareness of the therapeutic benefits of cannabis for managing chronic conditions, and enhanced prescriber confidence in its efficacy. According to the Penington Institute, in 2025, medicinal cannabis sales experienced a 28.5% decrease in the second half of the year compared to the first half, signaling a notable shift after several years of rapid growth.

A significant challenge impeding further market growth remains the complex and often inconsistent regulatory landscape across federal and state jurisdictions. This complexity impacts prescription processes and the timely availability of new products on the Australian Register of Therapeutic Goods. Additionally, the market's current reliance on imported cannabis products poses an impediment to the sustained growth and competitiveness of the nascent domestic cultivation and manufacturing sectors.

Key Market Drivers

Regulatory Reforms Driving Market Growth
Progressive regulatory reforms and sustained government support are pivotal in shaping the Australia Legal Cannabis Market, primarily by enhancing patient access and bolstering prescriber confidence. The Therapeutic Goods Administration's evolving frameworks, such as the revised therapeutic vaping framework introduced in 2025, streamline the process for medical practitioners and consumers. This regulatory evolution is directly reflected in new product registrations that expand available treatment options. According to a June 2026 report by SMBtech, Australian healthcare company Mood State Medical registered the Grenco Medical ELITE II therapeutic cannabis vaporiser on the Australian Register of Therapeutic Goods, providing a new regulated vaporisation option under the TGA's 2025 reforms. These ongoing reforms are critical for clarifying legal frameworks, reducing ambiguity, and fostering an environment conducive to responsible market development and growth.

Expansion of Domestic Cultivation and Manufacturing
The expansion of domestic cultivation and manufacturing infrastructure represents another critical driver for the Australian market. This growth addresses the historical reliance on imported products, strengthening local supply chains and promoting self-sufficiency. Increased investment in local facilities not only ensures product quality and consistency but also stimulates economic activity within the sector. According to Australia's Department of Health and Aged Care, as of December 2025, there were 39 approved medicinal cannabis cultivators and producers, with 38 licensed to cultivate and produce, and 22 licensed to manufacture. Furthermore, efforts to enhance local production capabilities aim to make medicinal cannabis more accessible and affordable for Australian patients. According to SMBtech, in 2026, Australia currently has more than one million active medicinal cannabis patients.

Download Free Sample Report

Key Market Challenges

Fragmented Regulation Impedes Market Expansion
The intricate and often fragmented regulatory framework spanning federal and state jurisdictions presents a considerable obstacle to the expansion of Australia's legal cannabis market. This complex landscape directly affects the efficiency of prescription processes and impedes the prompt introduction of new cannabis products onto the Australian Register of Therapeutic Goods. Such inconsistencies create uncertainty for prescribers and restrict patient access to a broader range of therapeutic options.

Decline in Authorised Prescriber Approvals Highlights Regulatory Barriers
The regulatory inconsistencies are evident in differing trends across access pathways. For instance, according to the Penington Institute, Authorised Prescriber (AP) approvals, which constitute the primary route for medicinal cannabis access, experienced a decline to 378,136 in the first six months of 2025, down from 408,417 in the latter half of 2024. This reduction in a key approval pathway highlights how the nuanced and sometimes shifting regulatory environment directly hampers market growth by creating barriers to patient access and product dissemination. This fragmentation not only adds administrative burdens but also delays the integration of new and innovative products, limiting the market's overall responsiveness and expansion.

Key Market Trends

Diversification of product formulations and rising edible cannabis demand.
The Australia Legal Cannabis Market is significantly influenced by the increasing diversification of product formulations and delivery methods. While oils and dried flower have historically dominated, the market now offers a broader array of products designed for diverse patient needs and preferences. This evolution includes the introduction of novel forms such as edibles, offering varied therapeutic experiences and greater convenience. According to the Penington Institute, 2025, in 'Cannabis in Australia 2025', access to edible cannabis medicines almost doubled over the past year, reflecting a notable shift in consumer demand and product availability.

Telehealth adoption expanding patient access.
Another pivotal trend is the widespread integration of telehealth for patient access. Telehealth platforms have revolutionized medicinal cannabis accessibility, especially for individuals in remote or underserved areas or those with mobility challenges. These online services streamline consultation and prescription processes, enabling faster access to treatment. The scalability of telehealth has been crucial for market expansion; for example, according to the Pharmacy Guild of Australia and the Australian Medical Association, October 2025, in a joint letter, a single doctor at Montu issued 72,000 prescriptions to 10,000 patients in just two years through telehealth clinics. This model has significantly lowered patient access barriers, despite recent regulatory scrutiny on clinical oversight.

Segmental Insights

Drivers of Medical Cannabis Growth in Australia
The Medical Use segment is demonstrably the fastest-growing within the Australia Legal Cannabis Market. This rapid expansion is primarily driven by progressive regulatory changes implemented by the Therapeutic Goods Administration (TGA), which has streamlined patient access through structured pathways such as the Special Access Scheme and the Authorised Prescriber Scheme. Concurrently, there is a rising patient demand for alternative therapies to manage various chronic conditions and an increasing awareness of the therapeutic benefits of medical cannabis. This, coupled with a discernible reduction in societal stigma, has led to greater acceptance among both patients and healthcare practitioners, further fueling the segment's growth.

Regional Insights

Regulatory Leadership and Pharma Ecosystem in Victoria
Victoria dominates the Australia Legal Cannabis Market primarily due to its pioneering legislative efforts and a supportive ecosystem for pharmaceutical development. The state was the first in Australia to legalize medicinal cannabis, establishing a clear regulatory framework that has fostered significant investment in the sector. This has led to robust activity in clinical research and the production of pharma-grade cannabis products within the region. Leading companies specializing in Good Manufacturing Practice-certified extraction and product standardization are established in Victoria. Additionally, the Victorian Government actively promotes industry growth through dedicated development plans and business assistance, further cementing its leadership in the national market.

Recent Developments

• In May 2025, Curaleaf International announced the launch of its branded medical cannabis products in Australia, marking a significant expansion into one of the world's rapidly growing medical cannabis markets. The initial offering comprised four distinct cannabis flower strains. These products were distributed through a partnership with Canngea, an Australian licensed manufacturer and wholesaler. This strategic entry underscored Curaleaf International's commitment to local collaboration, ensuring that Australian patients and healthcare professionals gained access to a proven portfolio of cannabis medicines.
• In July 2024, Wellnex Life, in a joint venture with One Life Botanicals, launched a new medicinal cannabis brand named Wellness Life for the Australian Special Access Scheme (SAS) market. This collaboration also included Chemist Warehouse as a partner, aiming to position Wellness Life as a preferred brand in Australia’s expanding medicinal cannabis sector. The partnership enabled access to high-quality, locally produced, and manufactured medicinal cannabis products at competitive prices, demonstrating a strategic move to address patient needs and increase market penetration through established retail channels.
• In April 2024, Aurora Cannabis Inc., through its subsidiary MedReleaf Australia, expanded its portfolio in the Australian legal cannabis market with the introduction of a new range of premium dried cannabis flower products. These included proprietary cultivars such as Black Jelly, Chemango Kush, and Moon Berry, alongside a relaunch of Vespera. Developed and manufactured at EU-GMP and TGA-GMP certified facilities, these products became available for prescription by medical professionals, aiming to provide a broader selection and cater to the increasing patient demand for diverse and affordable high-quality medical cannabis solutions in Australia.
• In March 2024, Aurora Cannabis Inc., in conjunction with its subsidiary MedReleaf Australia, introduced a new line of medical cannabis pastilles for prescription by doctors in Australia. This product launch diversified the available treatment options for patients in the Australian legal cannabis market, offering three formats: THC, CBD, and a balanced THC/CBD option. The initiative aimed to support the ongoing growth and development of the Australian market by providing innovative and differentiated products to enhance patient access and choice. These novel pastilles represented a commitment to expanding the premium medical cannabis offerings within the region.

Key Market Players

• Canopy Growth Corporation
• Aurora Cannabis Inc.
• Tilray Brands Inc.
• Cronos Group Inc.
• GW Pharmaceuticals plc
• Aphria Inc.
• Organigram Holdings Inc.
• Hexo Corp.
• Althea Group Holdings Limited
• Little Green Pharma Ltd

By Source	By Derivatives	By Cultivation	By End Use	By Region
Hemp Marijuana	CBD THC Others	Indoor Cultivation Greenhouse Cultivation Outdoor Cultivation	Industrial Use Medical Use Recreational Use	Australia Capital Territory & New South Wales Northern Territory & Southern Australia Western Australia Queensland Victoria & Tasmania

Report Scope:

In this report, the Australia Legal Cannabis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Australia Legal Cannabis Market, By Source:

• Hemp
• Marijuana

• Australia Legal Cannabis Market, By Derivatives:

• CBD
• THC
• Others

• Australia Legal Cannabis Market, By Cultivation:

• Indoor Cultivation
• Greenhouse Cultivation
• Outdoor Cultivation

• Australia Legal Cannabis Market, By End Use:

• Industrial Use
• Medical Use
• Recreational Use

• Australia Legal Cannabis Market, By Region:

• Australia Capital Territory & New South Wales
• Northern Territory & Southern Australia
• Western Australia
• Queensland
• Victoria & Tasmania